Trial Profile

A comparison of once and twice 1mg ARS-1 and once and twice 0.3mg EpiPen, monitoring BP and HR every 5 minutes

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 10 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Epinephrine (Primary) ; Epinephrine; Epinephrine
Indications Anaphylaxis; Respiratory tract infections
Focus Adverse reactions; Pharmacodynamics
Sponsors ARS Pharmaceuticals

Most Recent Events

24 Oct 2024 According to an ARS Pharmaceuticals media release, data from this study will be presented on Friday, October 25 at the 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting taking place in Boston, Massachusetts.
25 Apr 2022 New trial record
28 Feb 2022 Results presented at the 2022 Annual Meeting of the American Academy of Allergy, Asthma and Immunology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com